4i

4i (CHEMBL1269981) is a 5-HT3 receptor antagonist,It modulates the serotonergic system.

O4I1 is an effective Oct3/4 inducer.

IL4I1-IN-1 is a selective inhibitor of interleukin 4 induced protein 1 (IL4I1). It suppresses the IL4I1-mediated oxidation and deamination of phenylalanine, thereby reducing the production of phenylpyruvate, H2O2, and NH3. This compound holds potential for research into cancers with high IL4I1 expression, such as endometrial cancer, ovarian cancer, and triple-negative breast cancer.

O4I2 is an effective Oct3/4 inducer in various human cell lines including human fibroblasts.

PROTAC-O4I2, a PROTAC ligand targeting splicing factor 3B1 (SF3B1), induced FLAG-SF3B1 degradation in K562 cells with an IC50 value of 0.244 μM. PROTAC-O4I2 induced apoptosis in K562 WT cells.

O4I4 is an OCT4-inducing compound capable of activating endogenous OCT4 and its associated signaling pathways in a variety of cell lines, with the advantage of metabolic stability.Oct4-inducing Compound 4 has shown anti-aging effects in Cryptobacterium hidradii nematodes and Drosophila, and O4I4 can be used as a substitute for exogenous OCT4 to reprogram human fibroblasts to a pluripotent state, with potential applications in regenerative medicine.

Nec-34i is a potent and selective RIPK1 inhibitor (IC50 = 3.6 nM). It protects cells from TNF-α induced necroptosis, used in systemic inflammation research.

Ub4ix, a DUB/26S proteasome inhibitor, safeguards K48-linked Ub chains against cleavage by deubiquitinating enzymes (DUBs) and inhibits the proteasomal degradation of Ub-tagged proteins. Additionally, it diminishes the viability of Hela cells and triggers apoptosis, exhibiting an IC 50 value of 1.6 μM.

LTB4-IN-1 (Anti-inflammatory agent 2, Compound 6) belongs to small molecule inhibitors and is a leukotriene B4 (LTB4) synthesis inhibitor (IC50 = 70 nM) with good anti-inflammatory activity. This compound can be used in experimental research on inflammation-related diseases.

KDM4-IN-4 is a histone lysine demethylase 4 (KDM4) inhibitor that primarily targets the Tudor domain of KDM4A and exhibits anticancer activity. KDM4-IN-4 has an affinity for the KDM4A Tudor domain of approximately 80 μM. KDM4-IN-4 inhibits the binding of H3K4Me3 to the Tudor domain in cells, with an EC50 of 105 μM. KDM4-IN-4 can be used in cancer research.

Zavondemstat (QC8222) is an orally active, selective inhibitor of the histone lysine demethylase 4 (KDM4) family, with an IC₅₀ of ≤ 0.08 μM against human KDM4A–D and a K₊₀ of 0.52 μM against human KDM4C. Zavondemstat activates tumor suppressor genes, induces apoptosis, causes S-phase cell cycle arrest, and inhibits cancer cell proliferation. In in vivo studies, Zavondemstat inhibits tumor growth and induces tumor regression. Zavondemstat can be used in cancer research.

TLR4-IN-C34 is an inhibitor of TLR4, and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis

KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.

SID 3712249 is an inhibitor of the biogenesis of microRNA-544 (miR-544).

Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor with IC50 = 1.1~2.6 nM for TrkA/TrkB/TrkC and antinociceptive effects. It is also a selective type II PTK6 inhibitor with IC50 = 76 nM and has antitumor effects.

CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM). It is selective for IL-4 over IL-13 (EC50= 18.2 μM). IL-4 inhibitor inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes (EC50= 3.1 μM), indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway.

IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.

IRAK4-IN-8 (VI-177) is an IRAK4 inhibitor used to study diseases related to cancer and inflammation.

EPZ032597 is a novel selective inhibitor of SMYD2 with an IC50 of 16 nM. EPZ032597 has anticancer activity and can be used to prevent and treat pancreatic cancer.

(3,5-Dimethyl-4-isoxazolyl)methanol ,with CAS No. 19788-36-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. (3,5-Dimethyl-4-isoxazolyl)methanol provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

4-Isopropylaniline ,with CAS No. 99-88-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 4-Isopropylaniline provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

(S)-4-Isopropyl-2-oxazolidinone ,with CAS No. 17016-83-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. (S)-4-Isopropyl-2-oxazolidinone provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

4'-(2-Methylpropyl)acetophenone (4-Isobutylacetophenone) is used as pharmaceutical intermediates.